TP53 and neoplasm: For genetic tumour characteristics such as TP53 mutation status, HRD-status, BRCA1-deficiency due to biallelic inactivation by mutations (somatic/germline and LOH) or promoter hypermethylation it is evident in Fig. 4E that substantial proportions of tumours are found in both immune groups.